A5053436400- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune cells in cancer
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Hemoglobinopathies and Related Disorders
- CAR-T cell therapy research
- Blood disorders and treatments
- T-cell and B-cell Immunology
- T-cell and Retrovirus Studies
- NF-κB Signaling Pathways
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- Antifungal resistance and susceptibility
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Cytomegalovirus and herpesvirus research
- Biosimilars and Bioanalytical Methods
- Neurological Complications and Syndromes
- Chronic Lymphocytic Leukemia Research
- Erythropoietin and Anemia Treatment
Washington University in St. Louis
2015-2024
Pediatrics and Genetics
2018
St. Louis Children's Hospital
2018
Donor hematopoietic clones with pathogenic mutations engraft and persist in unrelated stem cell transplant recipients.
Abstract Toll-like receptor 2 (TLR2) is a member of the TLR family receptors that play central role in innate immunity. In addition to regulating effector immune cells, where it recognizes wide variety pathogen-associated and nonpathogen-associated endogenous ligands, TLR2 expressed hematopoietic stem cells (HSCs). Its HSCs, however, not well understood. Furthermore, augmented signaling associated with myelodysplastic syndrome, an HSC disorder characterized by ineffective hematopoiesis high...
Highlights•Early alemtuzumab allowed early immune recovery despite ablation.•Systemic infections similarly tracked reconstitution.•Infection patterns were similar after related and unrelated transplants.ABSTRACTHematopoietic stem cell transplantation (HSCT) is a therapeutic option for many nonmalignant disorders (NMD) curative or prevents disease progression. Reduced-intensity conditioning (RIC) in HSCT NMD may reduce regimen-related acute toxicities late complications. Myeloablation often...
Chronic granulomatous disease (CGD) is an immune deficiency characterized by defective neutrophil function and increased risk of life-threatening infections. Allogeneic hematopoietic cell transplantation curative for CGD, conditioning regimen impacts transplant-related outcomes. We report a single-center prospective study (NCT01821781) four patients with CGD transplanted using reduced-intensity (RIC) containing alemtuzumab, fludarabine, melphalan, thiotepa. Patients had early reconstitution...
Toll-like receptor 2 (TLR2) expression is increased on hematopoietic stem and progenitor cells (HSPCs) of patients with myelodysplastic syndromes (MDS), enhanced TLR2 signaling thought to contribute MDS pathogenesis. Notably, heterodimerizes TLR1 or TLR6, while high associated lower-risk disease, but not TLR1, correlates higher-risk disease. This raises the possibility heterodimer-specific effects in MDS, work described here, we tested specific modulation TLR1/2 versus TLR2/6 premalignant...
Allogeneic hematopoietic cell transplantation (HCT) is indicated in several malignant and non-malignant disorders. Graft versus host disease (GVHD) a significant cause of morbidity mortality following HCT. Steroid therapy the first only established treatment modality for acute GVHD (aGVHD). Severe aGVHD has 50% response rate, especially when gut or liver are involved [1-2]. Survival steroid refractory poor (mortality 2-4 months) due to paucity effective therapeutic alternatives [1]....
Chronic granulomatous disease (CGD) is a primary immune deficiency with risk of life threatening infections, autoimmunity, and inflammatory complications. The only known cure allogeneic hematopoietic stem cell transplant (HSCT). Myeloablative conditioning regimens have been associated significant toxicities, including infection, graft-versus-host (GVHD) sinusoidal obstructive syndrome (SOS). Reduced intensity (RIC) recently used but concerns for mixed chimerism, failed engraftment, delayed...
Background Recipients of successful allogeneic hematopoietic stem cell transplant (HSCT) for sickle disease (SCD) have hemoglobin S levels that reflect those the donor. SCD related organ damage targets vital organs and is variable based on age severity, can be further compromised by complications. Organ function parameters are generally not primary end-points clinical trials but need longitudinal follow up. This study aims to describe in recipients followed one or more years after HSCT SCD....